These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 20133198)
41. [Proteomic analysis of Plasmodium, the causal agent of Malaria]. Castro R I; Rodríguez G Mdel C Salud Publica Mex; 2009; 51 Suppl 3():S395-402. PubMed ID: 20464213 [TBL] [Abstract][Full Text] [Related]
42. Discovery of the hypnozoite and a new theory of malarial relapse. Krotoski WA Trans R Soc Trop Med Hyg; 1985; 79(1):1-11. PubMed ID: 3922096 [No Abstract] [Full Text] [Related]
43. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Goller JL; Jolley D; Ringwald P; Biggs BA Am J Trop Med Hyg; 2007 Feb; 76(2):203-7. PubMed ID: 17297026 [TBL] [Abstract][Full Text] [Related]
44. Getting down to malarial nuts and bolts: the interaction between Plasmodium vivax merozoites and their host erythrocytes. Rayner J Mol Microbiol; 2005 Mar; 55(5):1297-9. PubMed ID: 15720540 [TBL] [Abstract][Full Text] [Related]
45. Malaria Eradication and the Hidden Parasite Reservoir. Markus MB Trends Parasitol; 2017 Jul; 33(7):492-495. PubMed ID: 28366603 [TBL] [Abstract][Full Text] [Related]
46. Malaria: anti malarial resistance and policy ramifications and challenges. Kshirsagar NA J Postgrad Med; 2006; 52(4):291-3. PubMed ID: 17102549 [TBL] [Abstract][Full Text] [Related]
47. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. Chen N; Auliff A; Rieckmann K; Gatton M; Cheng Q J Infect Dis; 2007 Apr; 195(7):934-41. PubMed ID: 17330782 [TBL] [Abstract][Full Text] [Related]
48. Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis. Jiménez BC; Navarro M; Huerga H; López-Román E; Mendoza A; López-Vélez R J Travel Med; 2006; 13(6):373-5. PubMed ID: 17107431 [TBL] [Abstract][Full Text] [Related]
49. Neglect of Plasmodium vivax malaria. Baird JK Trends Parasitol; 2007 Nov; 23(11):533-9. PubMed ID: 17933585 [TBL] [Abstract][Full Text] [Related]
50. Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates. Hobbs CV; Dixit S; Penzak SR; Sahu T; Orr-Gonzalez S; Lambert L; Zeleski K; Chen J; Neal J; Borkowsky W; Wu Y; Duffy PE PLoS One; 2014; 9(12):e115506. PubMed ID: 25541998 [TBL] [Abstract][Full Text] [Related]
51. The efficacy of artemether (qinghaosu) in Plasmodium falciparum and P. vivax in Burma. Pe Than Myint ; Tin Shwe Southeast Asian J Trop Med Public Health; 1986 Mar; 17(1):19-22. PubMed ID: 3526578 [TBL] [Abstract][Full Text] [Related]
52. Sickle haemoglobin, G-6PD deficiency and malaria in western Orissa. Kar BC; Agrawal KC; Panda A J Assoc Physicians India; 1990 Aug; 38(8):555-7. PubMed ID: 2246194 [TBL] [Abstract][Full Text] [Related]
53. Hypnozoite dynamics for Plasmodium vivax malaria: The epidemiological effects of radical cure. Mehra S; Stadler E; Khoury D; McCaw JM; Flegg JA J Theor Biol; 2022 Mar; 537():111014. PubMed ID: 35016895 [TBL] [Abstract][Full Text] [Related]
54. Clinical experience with halofantrine in the treatment of malaria. Horton RJ; Parr SN; Bokor LC Drugs Exp Clin Res; 1990; 16(10):497-503. PubMed ID: 2100732 [TBL] [Abstract][Full Text] [Related]
55. KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Zeeman AM; van Amsterdam SM; McNamara CW; Voorberg-van der Wel A; Klooster EJ; van den Berg A; Remarque EJ; Plouffe DM; van Gemert GJ; Luty A; Sauerwein R; Gagaring K; Borboa R; Chen Z; Kuhen K; Glynne RJ; Chatterjee AK; Nagle A; Roland J; Winzeler EA; Leroy D; Campo B; Diagana TT; Yeung BK; Thomas AW; Kocken CH Antimicrob Agents Chemother; 2014; 58(3):1586-95. PubMed ID: 24366744 [TBL] [Abstract][Full Text] [Related]
56. A novel immortalized hepatocyte-like cell line (imHC) supports in vitro liver stage development of the human malarial parasite Plasmodium vivax. Pewkliang Y; Rungin S; Lerdpanyangam K; Duangmanee A; Kanjanasirirat P; Suthivanich P; Sa-Ngiamsuntorn K; Borwornpinyo S; Sattabongkot J; Patrapuvich R; Hongeng S Malar J; 2018 Jan; 17(1):50. PubMed ID: 29370800 [TBL] [Abstract][Full Text] [Related]
57. An Activation-Clearance Model for Plasmodium vivax Malaria. Mehra S; McCaw JM; Flegg MB; Taylor PG; Flegg JA Bull Math Biol; 2020 Feb; 82(2):32. PubMed ID: 32052192 [TBL] [Abstract][Full Text] [Related]
59. Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Krotoski WA; Garnham PC; Cogswell FB; Collins WE; Bray RS; Gwasz RW; Killick-Kendrick R; Wolf RH; Sinden R; Hollingdale M Am J Trop Med Hyg; 1986 Mar; 35(2):263-74. PubMed ID: 3513645 [TBL] [Abstract][Full Text] [Related]
60. Defining the biology component of the drug discovery strategy for malaria eradication. Leroy D; Campo B; Ding XC; Burrows JN; Cherbuin S Trends Parasitol; 2014 Oct; 30(10):478-90. PubMed ID: 25131411 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]